Search

Displaying results 1781 - 1790 of 8170 in total
  1. Drug

    Caplacizumab

    go.drugbank.com/drugs/DB06081
    ApprovedInvestigational

    Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression

  2. Drug

    Bilastine

    go.drugbank.com/drugs/DB11591
    Approved

    Bilastine is a novel new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and prolonged duration of action.

  3. Drug

    Furaprevir

    go.drugbank.com/drugs/DB12785
    Investigational

    Furaprevir is under investigation in clinical trial NCT01523990 (A Study to Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected Patients).

  4. Drug

    Bentoquatam

    go.drugbank.com/drugs/DB00516
    Approved

    Bentoquatam is a topical medication intended to act as a shield against exposure to the irritating substance urushiol, found in plants such as poison ivy or poison oak. Bentoquatam contains bentonite, a clay, and is only effective as lon...

  5. Drug

    Quercus alba pollen

    go.drugbank.com/drugs/DB10376
    Approved

    It can be subcutaneously administered to initiate an immune response in case of an allergic reaction.

  6. Drug

    Metixene

    go.drugbank.com/drugs/DB00340
    Approved

    Metixene (or methixene) is a anticholinergic used as an antiparkinsonian agent.

  7. Drug

    Rucaparib

    go.drugbank.com/drugs/DB12332
    ApprovedInvestigational

    Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. … androgen receptor–directed therapy, confirming clinical benefit for an indication that previously had accelerated approval.

    Categories: Cytochrome P-450 CYP1A2 Inducers, P-glycoprotein inhibitors
  8. Drug

    Verzistobart

    go.drugbank.com/drugs/DB18895
    Investigational

    Verzistobart is under investigation in clinical trial NCT06056895 (Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma).

  9. Drug

    PF-03382792

    go.drugbank.com/drugs/DB12949
    Investigational

    Pf 03382792 is under investigation in clinical trial NCT01045863 (To Evaluate Safety, Tolerability, Plasma Drug Levels And Other Biological Effects In Healthy Volunteers).

  10. Drug

    Afamitresgene autoleucel

    go.drugbank.com/drugs/DB18592
    ApprovedInvestigational

    [L51114] MAGE-A4 is an intracellular cancer-testis antigen that is overexpressed by cancer cells in synovial sarcoma. … antigen A4 (MAGE-A4)-directed genetically modified autologous T cell immunotherapy product consisting of CD4 and CD8 positive T cells transduced with a self-inactivating lentiviral vector (LV) expressing an

    Synonyms: AUTOLOGOUS CD4+ AND CD8+ T CELLS OBTAINED BY LEUKAPHERESIS, TRANSDUCED WITH AN HIV-DERIVED SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING AN ENHANCED-AFFINITY T CELL RECEPTOR (TCR) SPECIFIC FOR THE